You are here: Industry Insights > GEJ

News List

EC approves BMS’ Opdivo as adjuvant treatment for oesophageal or GEJ cancer patients pharmatimes
August 03, 2021
Bristol Myers Squibb (BMS) has announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with oesophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease ...
MSD’s Keytruda scores EU approval in certain oesophageal cancer patients pharmatimes
July 02, 2021
MSD’s immunotherapy Keytruda has received approval from the European Commission (EC) in combination with chemotherapy as a first line treatment for certain oesophageal cancer patients.
FDA Approves Nivolumab for Resected Esophageal or GEJ Cancer americanpharmaceuticalreview
May 24, 2021
On May 20, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received ...
Amgen to Acquire Five Prime Therapeutics for $1.9B contractpharma
March 05, 2021
Amgen entered an agreement to acquire Five Prime Therapeutics for approximately $1.9 billion in cash. This acquisition adds Five Prime's innovative pipeline of immuno-oncology and targeted cancer therapies to Amgen's oncology portfolio.
AZ, Daiichi Sankyo’s Enhertu wins US approval for HER2-positive gastric cancer pharmatimes
January 19, 2021
AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval in the US for the treatment of locally advanced/metastatic HER2-positive gastric or gastroesophageal junction (GEJ) ...
FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer pharmaceutical-business-review
December 22, 2020
Merck announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum and ...